Lee Sang-hoon (executive)

Lee Sang-hoon
이상훈
Born1963 (1963)
Education
OccupationBusiness executive
Years active2016–present
TitleCEO of ABL Bio

Lee Sang-hoon (Korean: 이상훈; born January 1963)[1] is a South Korean biologist and business executive. He is the founder and CEO of ABL Bio.

In November 2025, Forbes estimated his net worth at US$1.5 billion.[2]

Early life and education

From 1982 to 1989, Lee studied biology at Seoul National University, where he earned a Bachelor of Science, followed by a Master’s degree in developmental biology.[3] In 1994, he completed a Ph.D. in Molecular, Cellular and Developmental Biology at the Ohio State University.[2] Lee completed postdoctoral fellowships at Harvard Medical School, University of California, San Francisco, and Stanford Medical School.[4]

Career

He led research at several companies, including AstraZeneca, Genentech, and Exelixis.[5]

In 2008, Lee co-founded PharmAbcine. He then served as head of the biotech division at Hanwha Solutions.

In 2016, Lee founded ABL Bio. The company listed on the KOSDAQ in 2018.[6]

He became a billionaire in 2025 after ABL Bio signed a licensing and research deal with Eli Lilly.[6]

References

  1. ↑ 김은혜 (2025-06-27). "[Who Is ?] 이상훈 에이비엘바이오 대표이사". 비즈니스포스트 (in Korean). Retrieved 2025-11-28.
  2. 1 2 "Lee Sang-hoon". Forbes. Retrieved 2025-11-28.
  3. ↑ Ahn, Joong-hyun; Lee, Kyeon-eun (2025-11-12). "KOSDAQ Reverses with Biotech 52-Week Highs". The Chosun Daily (in Korean). Retrieved 2025-11-28.
  4. ↑ Jeong-yeo, Lim (2019-05-12). "[Herald Interview] [Bio Startups] Buying and selling technology vital to ABL Bio business model". The Korea Herald (in Korean). Retrieved 2025-11-28.
  5. ↑ 기자, 김윤선 (2022-01-28). "이상훈 ABL바이오 대표, 주식부호 순위 급등". CEOSCOREDAILY (in Korean). Retrieved 2025-11-28.
  6. 1 2 Kang, John. "Deal With Eli Lilly Propels Founder Of Korean Biotech Firm Into Billionaire Ranks". Forbes. Retrieved 2025-11-28.